Bristol Nabs Immunotherapy’s First FDA Nod for Small Cell Lung Cancer

The FDA on Friday approved Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy, nivolumab (Opdivo), for SCLC patients who have failed at least two other treatments. The approval marks the first new treatment for SCLC in two decades.